Business Description
Staidson (Beijing) Biopharmaceuticals Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE100001237
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.05 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.07 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 7.91 | |||||
Beneish M-Score | -3.23 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -5 | |||||
3-Year EBITDA Growth Rate | -38.8 | |||||
3-Year EPS without NRI Growth Rate | -40 | |||||
3-Year FCF Growth Rate | -16.9 | |||||
3-Year Book Growth Rate | -13.8 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 52.43 | |||||
9-Day RSI | 56.21 | |||||
14-Day RSI | 56.84 | |||||
6-1 Month Momentum % | 15.6 | |||||
12-1 Month Momentum % | -39.01 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.14 | |||||
Quick Ratio | 1.03 | |||||
Cash Ratio | 0.24 | |||||
Days Inventory | 132.46 | |||||
Days Sales Outstanding | 62.49 | |||||
Days Payable | 371.08 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | -0.44 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 81.92 | |||||
Operating Margin % | -54.36 | |||||
Net Margin % | -65.98 | |||||
FCF Margin % | -43.99 | |||||
ROE % | -22.63 | |||||
ROA % | -17.88 | |||||
ROIC % | -19.84 | |||||
ROC (Joel Greenblatt) % | -80.26 | |||||
ROCE % | -18.16 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 8.3 | |||||
PB Ratio | 3.59 | |||||
Price-to-Tangible-Book | 4.13 | |||||
EV-to-EBIT | -16.68 | |||||
EV-to-EBITDA | -16.68 | |||||
EV-to-Revenue | 9.51 | |||||
EV-to-FCF | -21.19 | |||||
Price-to-Median-PS-Value | 0.98 | |||||
Earnings Yield (Greenblatt) % | -6 | |||||
FCF Yield % | -4.56 | |||||
Forward Rate of Return (Yacktman) % | -19.05 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Staidson (Beijing) Biopharmaceuticals Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ¥) | 377.2 | ||
EPS (TTM) (Â¥) | -0.53 | ||
Beta | 1.42 | ||
Volatility % | 43.46 | ||
14-Day RSI | 56.84 | ||
14-Day ATR (Â¥) | 0.478808 | ||
20-Day SMA (Â¥) | 6.9775 | ||
12-1 Month Momentum % | -39.01 | ||
52-Week Range (Â¥) | 5.41 - 13.33 | ||
Shares Outstanding (Mil) | 477.77 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Staidson (Beijing) Biopharmaceuticals Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Staidson (Beijing) Biopharmaceuticals Co Ltd Stock Events
Event | Date | Price(Â¥) | ||
---|---|---|---|---|
No Event Data |
Staidson (Beijing) Biopharmaceuticals Co Ltd Frequently Asked Questions
What is Staidson (Beijing) Biopharmaceuticals Co Ltd(SZSE:300204)'s stock price today?
When is next earnings date of Staidson (Beijing) Biopharmaceuticals Co Ltd(SZSE:300204)?
Does Staidson (Beijing) Biopharmaceuticals Co Ltd(SZSE:300204) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |